John R Chiminski Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 5 months ago
John R Chiminski has an estimated net worth of at least $40.5 million*, as of Dec. 4, 2024. They own shares of CTLT stock. They have sold 212,399 shares of CTLT stock since 2021, for an estimated $26.3 million.
John R Chiminski $CTLT SEC Form 4 Insider Trading
John R Chiminski has filed a total of 10 insider trades in $CTLT since 2021. Their most recent trade was a sale of 38,934 shares, made on Aug 25, 2022. Their largest trade was a sale of 64,031 shares, made on Oct 01, 2021. We estimate that they now own shares of $CTLT, worth an estimated $14.2 million.
Insider Trading at $CTLT
There have been a total of 137 insider trades reported at $CTLT since 2021, with 22,000 shares purchased and 3.9 million shares sold. The most active insider traders in $CTLT stock have been Michael J Grippo, Scott Gunther, and Steven L Fasman. The most recent trade was a sale of 2,800 shares reported by Michelle R Ryan (None), made on Nov 11, 2024.
History of Insider Stock Trades by John R Chiminski
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
CTLT
|
Sale | 38,934 | Aug 25, 2022 | Aug. 26, 2022, 8:16 p.m. |
|
CTLT
|
Sale | 9,691 | Jul 26, 2022 | July 28, 2022, 7:41 p.m. |
BLI
|
Purchase | 18,000 | Mar 11, 2022 | March 15, 2022, 8:14 p.m. |
|
CTLT
|
Sale | 12,700 | Oct 01, 2021 | Oct. 4, 2021, 8 p.m. |
|
CTLT
|
Sale | 21,245 | Oct 01, 2021 | Oct. 4, 2021, 8 p.m. |
|
CTLT
|
Sale | 64,031 | Oct 01, 2021 | Oct. 4, 2021, 8 p.m. |
|
CTLT
|
Sale | 4,888 | Oct 01, 2021 | Oct. 4, 2021, 8 p.m. |
|
CTLT
|
Sale | 26,662 | Oct 01, 2021 | Oct. 4, 2021, 8 p.m. |
|
CTLT
|
Sale | 4,601 | Oct 01, 2021 | Oct. 4, 2021, 8 p.m. |
|
CTLT
|
Sale | 18,510 | Oct 01, 2021 | Oct. 4, 2021, 8 p.m. |
|
CTLT
|
Sale | 11,137 | Jul 26, 2021 | July 27, 2021, 8 p.m. |
$CTLT Executives and Stock Owners with Insider Trades
-
Michael J Grippo, SVP, Strategy & Corp. Dev.
-
Scott Gunther, SVP, Quality & Reg. Affairs
-
Steven L Fasman, SVP & General Counsel
-
John R Chiminski, Chair & CEO
-
Alessandro Maselli, President & CEO
-
Aristippos Gennadios, Group Pres. Pharma & Consumer
-
Steven L Fasman, EVP & Chief Admin Officer
-
Ricky Hopson, Pres. Clinical Dev Supply Div
-
Ricardo Pravda, SVP & Chief HR Officer
-
Lorenzo Carletti, SVP Global Ops Ph & Cons Hlth
-
Thomas P Castellano, SVP, Chief Financial Officer
-
Thomas W Hawkeswood, Pres. Pharma Prod Delivery Div
-
Patricia Hunt, Pres. Consumer Health Div
-
Ricky Hopson, Pres. BioProduct Delivery, CoS
-
Manja Boerman, Pres. BioModalities Division
-
Jonathan Arnold, Pres. Oral & Specialty Deliv.
-
Ricardo Pravda, Chief Transformation Officer
-
Michael A. Riley, Pres. Bio Product Delivery Div
-
Charles Lickfold, SVP, CIO
-
Ricky Hopson, VP, Chief Accounting Officer
-
John R Chiminski, Executive Chair
-
Ricky Hopson, Pres, Clinical Dev & Supply
-
Jonathan Arnold, SVP & Chief Commercial Ofcr
-
Joseph Anthony Ferraro, SVP, General Counsel, CCO
-
Jonathan Arnold, SVP, CCO & Div. Head BioP Del.
-
Kay A Schmidt, SVP, Technical Operations
-
Kay A Schmidt, SVP, Enterprise Functions
-
Mario Gargiulo, SVP Global Ops Biologics
-
Matti Masanovich, SVP, Chief Financial Officer
-
Karen Flynn, Chief Commercial Officer
-
Mario Gargiulo, SVP, Ops, Biologics Europe
-
Mario Gargiulo, SVP Global Ops Large Molecule
-
Ricci S Whitlow, President, CSS
-
Alessandro Maselli, President & COO
-
Lisa Evoli, SVP, Chief HR Officer
-
John J Greisch, Executive Chair
-
David Mcerlane, Group President, Biologics
-
Aristippos Gennadios, President Softgel & Oral Tech
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.